TP53 and neoplasm: The synthesized trastuzumab-bound p53 mRNA–lipid nanoparticles alleviated the liver toxicity of the antibody-free mRNA–lipid system, enhanced the targeting of Her-2-positive tumor cells, and exhibited superior therapeutic potential [161].